ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zepbound (tirzepatide by Year
Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M)
Eli Lilly Zepbound (tirzepatide: $13,542M in FY2025, up 174.9% from a year earlier.
Where the FY2025 figure comes from
“|| Zepbound (1) | 13,484 | 58 | 13,542 | 4,926 | 175”
Source: Form 10-K FY2025 (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13,542 | +174.9% | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 4,926 | +2,701.9% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 176 | – | Form 10-K FY2023 (filed 2024-02-21) ↗ |
Breakdown
What makes up zepbound (tirzepatide
Cite this data
StockData. (2026). Eli Lilly Zepbound (tirzepatide ($M), annual FY2023–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zepbound-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.